Oxaliplatine

Phase 2Small molecule

TThe Lymphoma Academic Research Organisation

Oxaliplatine is one of 65 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Pancreatic CancerActive, not recruiting

LymphomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Oxaliplatine

TThe Lymphoma Academic Research Organisation

Phase 2

1 7

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Lymphoma

NCT04984837

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

Completed·IInstitut Cancerologie de l'Ouest·Phase 2·NCT02143219·72 enrolled

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Active, not recruiting·OOslo University Hospital·Phase 2/3·NCT02919787·140 enrolled

Lymphoma1 trial

Study of Lacutamab in Peripheral T-cell Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04984837·56 enrolled

Capecitabine1 trial

1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

Completed·UUnidad Integral de Investigación en Oncología S.L.·Phase 2·NCT00345696·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Oxaliplatine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxaliplatine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxaliplatine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Lymphoma Academic Research Organisation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe Lymphoma Academic Research Organisation

Oxaliplatine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Pancreatic Cancer2 trials

Lymphoma1 trial

Capecitabine1 trial

References

Drug Info

Quick Facts

Related News